Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ashis Chowdhury"'
Autor:
Aimee L. Dowling, Stuart Walbridge, Celine Ertekin, Sriya Namagiri, Krystal Camacho, Ashis Chowdhury, Jean-Paul Bryant, Eric Kohut, John D. Heiss, Desmond A. Brown, Sangamesh G. Kumbar, Yeshavanth Kumar Banasavadi-Siddegowda
Publikováno v:
Cells, Vol 12, Iss 21, p 2562 (2023)
Glioblastoma is the most common malignant primary brain tumor. The outcome is dismal, despite the multimodal therapeutic approach that includes surgical resection, followed by radiation and chemotherapy. The quest for novel therapeutic targets to tre
Externí odkaz:
https://doaj.org/article/a2a25bc8c4914f2f9d2697c28c7973a6
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0158876 (2016)
The Sm-like proteins (also known as Lsm proteins) are ubiquitous in nature and exist as hexa or heptameric RNA binding complexes. They are characterized by the presence of the Sm-domain. The Lsm1 through Lsm7 proteins are highly conserved in eukaryot
Externí odkaz:
https://doaj.org/article/ede3d50543724bb6a5f6d21866b3013b
Autor:
Mitchell Rock, Jean-Paul Bryant, Stuart Walbridge, Mahalia Dalmage, Sriya Namagiri, Ashis Chowdhury, Nancy Edwards, Sadhana Jackson, Abhik Ray-Chaudhury, John Heiss, Sangamesh Kumbar, Yeshavanth Kumar Banasavadi-Siddegowda
Purpose: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite standard treatment, the median survival of GBM patients is only 15 months. Enabled homolog (ENAH) is a member of the Ena/VASP protein family and regulates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5542754ecf2ff2a7710130a703942fe
https://doi.org/10.21203/rs.3.rs-2042472/v1
https://doi.org/10.21203/rs.3.rs-2042472/v1
Autor:
Yeshavanth Kumar Banasavadi-Siddegowda, Sriya Namagiri, Yoshihiro Otani, Hannah Sur, Sarah Rivas, Jean-Paul Bryant, Allison Shellbourn, Mitchell Rock, Ashis Chowdhury, Cole T Lewis, Toshihiko Shimizu, Stuart Walbridge, Sivarajan Kumarasamy, Ashish H Shah, Tae Jin Lee, Dragan Maric, Yuanqing Yan, Ji Young Yoo, Sangamesh G Kumbar, John D Heiss, Balveen Kaur
Publikováno v:
Neurooncol Adv
Background The prognosis of glioblastoma (GBM) remains dismal because therapeutic approaches have limited effectiveness. A new targeted treatment using MEK inhibitors, including trametinib, has been proposed to improve GBM therapy. Trametinib had a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eae910a5f1e7ff38b261f8b1c9b6bcfc
https://pubmed.ncbi.nlm.nih.gov/35875691
https://pubmed.ncbi.nlm.nih.gov/35875691
Autor:
John D. Heiss, Sriya Namagiri, Guruprasad Rachaiah, Toshihiko Shimizu, Yuanqing Yan, Hannah Sur, Prashant Chittiboina, Leomar Y. Ballester, Balveen Kaur, Amelie Vezina, Zhuang Zhengping, Cole T. Lewis, Ashis Chowdhury, Xiang Wang, Ji Young Yoo, Dragan Maric, Yoshihiro Otani, Sadhana Jackson, Yeshavanth Kumar Banasavadi-Siddegowda, Arunakumar Gangaplara, Sachin Kumar, Abhik Ray-Chaudhury
Publikováno v:
Neuro Oncol
Background Despite multi-model therapy of maximal surgical resection, radiation, chemotherapy, and tumor-treating fields, the median survival of glioblastoma (GBM) patients is less than 15 months. Protein arginine methyltransferase 5 (PRMT5) catalyze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1204e2620ea4f530d2e13c58908a4860
https://doi.org/10.1093/neuonc/noab014
https://doi.org/10.1093/neuonc/noab014
Autor:
Ashis Chowdhury, Aleksei Kondrashov, Sriya Namagiri, Abhik Ray-Chaudhury, Yeshavanth Kumar Banasavadi-Siddegowda, Saber Tadros
Publikováno v:
Neurosurgery
Hereditary cancer predisposition syndromes (HCS) become more recognizable as the knowledge about them expands, and genetic testing becomes more affordable. In this review, we discussed the known HCS that predispose to central and peripheral nervous s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::526ec4f4a6f769bd316b33800d917e0e
https://europepmc.org/articles/PMC8492608/
https://europepmc.org/articles/PMC8492608/
Autor:
Ashis Chowdhury, Shilpa Thammegowda, Toshihiko Shimizu, Hannah Sur, Yoshihiro Otani, Tae Jin Lee, Sriya Namagiri, John D. Heiss, Yesh Banasavadi, Ji Young Yoo, Jean-Paul Bryant, Dragan Maric, Cole T. Lewis, Sarah R. Rivas, Balveen Kaur, Stuart Walbridge
Publikováno v:
Neuro-Oncology. 23:vi79-vi80
With limited effective therapeutic strategies, the prognosis for glioblastoma (GBM) is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRMT5) is upregulated in GBM; its inhibition promotes apoptosis an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::721d1d9ba07c4fb286ccc04acf9e3583
https://doi.org/10.1093/neuonc/noab196.310
https://doi.org/10.1093/neuonc/noab196.310
Autor:
Shilpa Thammegowda, Abhik Ray-Chaudhury, Arunakumar Gangaplara, Dragan Maric, Sriya Namagiri, Hannah Sur, Sadhana Jackson, John D. Heiss, Yeshavanth Kumar Banasavadi-Siddegowda, Amelie Vezina, Ashis Chowdhury, Nancy A. Edwards
Publikováno v:
Neuro Oncol
INTRODUCTION Despite multi-model therapies that include maximal surgical resection, radiation, chemotherapy, and tumor treating fields, the median survival of Glioblastoma (GBM) patients is around 15 months. WASP-family verprolin homologous protein 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fdb7b35747f35c5aa4536bfeceb31c6
https://doi.org/10.1093/neuonc/noaa215.820
https://doi.org/10.1093/neuonc/noaa215.820
Autor:
Hannah Sur, Ji Young Yoo, Shilpa Thammegowda, Toshihiko Shimizu, Balveen Kaur, John D. Heiss, Yeshavanth Kumar Banasavadi-Siddegowda, Dragan Maric, Yoshihiro Otani, Sriya Namagiri, Ashis Chowdhury, Tae Jin Lee, Cole T. Lewis
Publikováno v:
Neuro Oncol
INTRODUCTION Glioblastoma (GBM) is the most common malignant primary brain tumor. With limited effective therapeutic strategies, prognosis for GBM is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2521f77903ed9d1ae38767f24137cee7
https://doi.org/10.1093/neuonc/noaa215.129
https://doi.org/10.1093/neuonc/noaa215.129
Publikováno v:
RNA. 13:998-1016
Decapping is a critical step in mRNA decay. In the 5′-to-3′ mRNA decay pathway conserved in all eukaryotes, decay is initiated by poly(A) shortening, and oligoadenylated mRNAs (but not polyadenylated mRNAs) are selectively decapped allowing their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a53debd00124e631eeb8b9ecbcbb6997
https://doi.org/10.1261/rna.502507
https://doi.org/10.1261/rna.502507